RUNX1::RUNX1T1 (AML1::ETO) t(8;21) Detection, Quantitative

Last Literature Review: September 2026 Last Update:
  • Use to detect and quantitate RUNX1::RUNX1T1 fusions arising from t(8;21)
  • Use to monitor for MRD in patients with a known history of RUNX1::RUNX1T1 fusions arising from t(8;21) and assess the risk of disease relapse

Testing for RUNX1::RUNX1T1 rearrangements may be useful in the evaluation of acute myeloid leukemia (AML) to aid in classification, inform prognosis, and guide therapeutic decision-making. RUNX1::RUNX1T1 fusion transcript testing may be used to monitor for minimal residual disease (MRD).  This test uses reverse transcription polymerase chain reaction (RT-PCR) to detect if a mutant transcript is present.

Genetics

RUNX1::RUNX1T1 fusions arising from t(8;21)

Test Interpretation

Analytic Sensitivity

Limit of quantitation: 1:50,000

Limit of detection: 1/100,000 RUNX1::RUNX1T1 t(8;21)-positive cells

Limitations

  • Translocations involving other genes or gene partners will not be identified.
  • Levels can only be reliably compared if the same laboratory and same sample type are used.

References